More than 43% of patients receiving an anti–programmed death (PD)-1 agent for adjuvant treatment of stage III/IV melanoma experience an acute immune-related adverse event (irAE), according to a recent multicenter study.
“Chronic irAEs, while usually low grade, occur more frequently than previously reported and particularly affect nonvisceral organs,” according to senior researcher Douglas Johnson, MD, an assistant professor of medicine of hematology/oncology at Vanderbilt